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From the earliest identification of different bacterial phenotypic states, researchers found 
under antibiotic exposure, there are some bacteria that can keep dormant in a non-growing state 
as persister cells. These dormant persister bacteria can revert back to the growing population 
when the antibiotics are removed. The formation of bacterial persister cells establishes 
phenotypic heterogeneity within a bacterial population and is important for increasing the 
chances of successfully adapting to environmental change. Persister cells were first discovered in 
Staphylococcus sp. in 1944 when penicillin failed to kill a small subpopulation of bacterial cells. 
Persisters exhibit temporary antibiotic-tolerant phenotype and the underlying mechanisms 
involved in the induction and regulation of persister cells formation have been investigated by 
the previous lab members regarding mechanisms of persistence in Borrelia burgdorferi and with 
Yin-Yang Model to illustrate persistent infection. This investigation focuses on the optimal 
treatment for persistent infection. Because current treatments for such chronic persistent 
infections are not effective and antibiotic phenotypic resistance is a significant issue. 
 The discovery of antibiotics and their widespread use represent a significant milestone in 
human history since the 20th century. However, their efficacy has declined at an alarming rate 
due to the spread of antibiotic resistance, and persistence and the evidence is accumulating that 
persister cells can contribute to the emergence of antibiotic resistance. Effective treatments for 
bacterial persistent infections can greatly improve patient outcome. A comprehensive overview 
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of anti-persister treatments suggests that development of drug combination treatments may 
represent a useful therapeutic approach. A typical drug for treating tuberculosis persistent 
infection includes pyrazinamide (PZA) which is combined with rifampin and isoniazid which kill 
growing bacteria. PZA is an anti-persister drug that inhibits unconventional drug targets such as 
proteins involved in energy metabolism and trans-translation. PZA in this triple drug 
combination therapy demonstrates a strong activity against persister cells, and based on this 
principle, we screened for pesister drugs like PZA and ranked drugs from six typical classes of 
antibiotics for their activity against non-growing Pseudomonas aeruginosa. Based on the ranking 
results, we formulated drug combinations that can effectively kill the heterogeneous population 
of Gram-negative bacteria in biofilm model. To further evaluate the activity of drug 
combinations in a relevant mouse model, we established a chronic pulmonary murine infection 
model. We found that consistent with our findings in vitro, the drug combinations are more 
effective against the persistent lung infection than the current standard of care treatment. Finally, 
we conclude that drug combinations consisting of drugs targeting both actively growing bacteria 
and non-growing persister cells can eradicate the Gram-negative bacteria biofilm related chronic 
infections. These findings lay the groundwork for possible improved treatment of persistent 
infections in the clinic. 
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Clinical Significance of Pseudomonas aeruginosa  
Pseudomonas aeruginosa is a hardly eradicated, opportunistic Gram-negative bacterium [1] 
that causes serious infections in hospitalized patients or people with compromised immune 
systems. Patients with burn wounds, cystic fibrosis, acute leukemia, organ transplants, and 
intravenous-drug users are at high risk for infections [2]. Because P. aeruginosa causes many 
nosocomial infections, epidemics within the hospitals have been reported [3, 4]. P. aeruginosa is 
a major pathogen in the cystic fibrosis (CF) lung, and it causes a persistent infection that cannot 
be eradicated by even the most aggressive antibiotic therapy [5]. This has been attributed to 
bacterial biofilms which are resistant or tolerant to antibiotic treatments and can evade host 
immune defense [6].  
 
Treatment of P. aeruginosa Infections and persisters 
Based on the Johns Hopkins Antibiotics Guide [7], high doses of synergistic antibiotic 
combinations (β-lactam + aminoglycoside) may improve outcomes of serious P. aeruginosa 
infections in immunocompromised hosts clinically and these combinations were determined 
against Pseudomonas aeruginosa from the sputum of patients with cystic fibrosis [8]. For 
multidrug resistant strains, colistin can be added to the above treatment [9]. Due to the increased 
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antibiotic resistance, the repertoire of effective agents against P. aeruginosa is limited [10], and 
thus better therapies are needed. 
Bacterial cells may escape the effects of antibiotics due to epigenetic changes; these cells are 
known as persisters [11]. Many chronic infections are associated with the ability of the bacteria 
to predominantly colonize body surfaces and tissues as multicellular aggregates such as biofilms 
[5, 12]. Formation of these sessile communities and their inherent resistance to antimicrobial 
agents are at the root of many persistent and chronic bacterial infections. The number of 
persisters in a growing population of bacteria rises in mid-log and reaches a maximum of 
approximately 1% at stationary state [13]. Similarly, slow-growing biofilms produce substantial 
numbers of persisters. The ability of a biofilm to limit the access of the immune system 
components, and the ability of persisters to sustain an antibiotic attack could then account for the 
recalcitrance of such infections in vivo and can cause frequent relapse after treatment. 
 
The Yin-Yang Model of Persistence 
 To better describe a dynamic and complex heterogeneous bacterial population consisting of 
growing (Yang) and non-growing persister cells (Yin) that are in varying growth and metabolic 
states in continuum [14]. There are small numbers of Yin bacterial population called persisters in 
the growing Yang bacterial population, and persisters can cause latent or persistent infections 
and there are Yang growing bacterial population in Yin non-growing bacterial cells which can 
cause active disease at the host level. This Yin-Yang model can also be attributed to the 
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heterogeneous population in a biofilm model because persisters can adopt varying sizes and 
shapes from regular morphology to altered morphologies as found in biofilms and L-form 
bacteria [15-17]. A typical persistent form of P. aeruginosa is mucoid biofilms in CF lung 
colonization. The biofilm form is a rather complex continuum with growing and dormant states 
that can be described and simplified using the Yin-Yang model [14]. 
 
Mechanisms of Persisters and Biofilm Forms of P. aeruginosa 
 The differentiation or maturation of P. aeruginosa biofilms in vitro depends on intercellular 
signaling systems or quorum sensing (QS) [18, 19]. QS systems in many Gram-negative bacteria 
rely on acylated homoserine lactones (AHLs), which are produced at high levels when cell 
density is high and act as ligands for transcriptional regulators. P. aeruginosa has been shown to 
form biofilm-like microcolonies in the lungs of CF patients and researchers found that quorum 
sensing signals found in patients’ lungs were only produced by isolated strains when they were 
grown in biofilms [20, 21]. These findings suggest that P. aeruginosa forms biofilms in the CF 
lung, possibly explaining the difficulty of treating this hardly-eradicated chronic infection.  
 
An optimized SYBR Green I/PI Assay for Rapid Viability Assessment for P. aeruginosa 
The most common method to assess the killing activity of antibiotics against stationary 
phase bacteria is through counting of viable cells grown on agar plates in colony forming unit 
(CFU) assay. A major disadvantage of CFU counting is the lengthy time (1-3 days) for bacteria 
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to grow on agar plates and CFU counting may miss the subpopulation of viable but non-
culturable bacteria that do not form CFUs. To more rapidly quantify the amount of live cells 
after drug treatment, we used a SYBR Green I/Propidium Iodide (PI) viability assay [22] which 
was developed to evaluate antibiotic susceptibility and to perform high-throughput drug screens 
in B. burgdorferi [23]. SYBR Green I is a high affinity dye that binds double-stranded DNA 
(dsDNA) and is commonly used to stain nucleic acids in PCR and flow cytometric analysis [24-
26]. SYBR Green I is a permeable dye that stains all live cells green, whereas PI is an 
impermeable dye that stains dead or damaged cells with compromised cell membrane red [27]. 
Therefore, fluorescence microscopy or fluorescence microplate readers can be used to measure 
the live/dead ratio of a bacterial sample as a rapid method to assess bacterial viability after drug 
treatment without CFU counts. Here, we applied the SYBR Green I/PI viability assay to P. 
aeruginosa and ranked six major classes of antibiotics in killing growing and stationary phase 
non-growing forms of P. aeruginosa compared with conventional CFU based viability assay. 
Using these methods, we also identified drug combinations that could more effectively eradicate 
persisters in stationary phase culture of P. aeruginosa as well as in biofilms in vitro and more 






Materials and Methods 
 
Bacterial strain, culture media and growth condition 
P. aeruginosa strain PAO-1 was obtained from Colin Manoil Lab, University of 
Washington, Seattle, WA. P. aeruginosa strain was cultured in tryptic soy broth (TSB) and 
tryptic soy agar (TSA) from Becton Dickinson (Franklin Lakes, NJ, USA) at 37 ℃. The culture 
was incubated at 37 ℃ with shaking at 200 rpm. After overnight incubation, stationary phase 
cultures were exposed to different antibiotics and incubated at indicated times before washing 
and plating on TSA plates for colony forming unit (CFU) enumeration. The plates were 
incubated at 37 ℃ incubator overnight. 
 
Preparation of antibiotics 
Stock solutions of antibiotics Cefuroxime, Colistin, Gentamicin, Clinafloxacin, Rifampicin, 
Sulfamethoxazole and Nitrofurantoin (Sigma Aldrich Co.) were prepared in the laboratory, filter-
sterilized and with appropriate solvents at 10 mg/ml. Each antibiotic (25 μM) was added into 500 
μL of stationary phase culture of P. aeruginosa and was incubated at 37 ℃ without shaking for 
various times. In addition, appropriate concentrations of the antibiotics were used for MIC 
determination using the microdilution method in 96-well plates (see below). 
 
Drug exposure assay by CFU counting on plates 
 7 
Viable bacterial cells were determined by CFU count after drug exposure at days 2, 4, 6 and 
10 as described [28]. First, bacterial suspensions (50 μL) after drug exposure were washed with 
fresh TSB medium twice and serial dilutions were prepared. 10 μL of each dilution was dropped 
onto TSA plates in triplicate followed by incubation at 37 ℃ overnight. The CFU/mL was 
calculated accordingly. 
 
SYBR Green I/PI assay for P. aeruginosa  
The staining dyes were prepared by mixing SYBR Green I/PI (10,000X stock, Invitrogen) 
with propidium iodide (20 mM, Sigma-Aldrich) in distilled water and the ratio of SYBR Green I 
to propidium iodide was 1:3 in 100 µl distilled H2O [23]. The drug treated samples were 
aliquoted and diluted 1:50 with fresh TSB medium. The SYBR Green I/PI dye mix (10 µL) was 
added to each 100 µL of sample. Each sample was vortexed and incubated at room temperature 
in the dark for 20 minutes. After incubation, each sample was transferred into 96-well plate. 
With excitation wavelength of 485 nm and 538 nm and 612 nm for green and red emission, 
respectively, the green and red fluorescence intensity was determined for each sample using a 
Synergy H1 microplate reader by BioTek Instruments (VT, USA). To generate the regression 
equation and regression curve of the relationship between the percentage of live bacteria and 
green/red fluorescent ratios, different proportions of live and 70% isopropyl alcohol killed dead 
cells were prepared (0:10, 1:4, 5:5, 4:1, 10:0) and both live and dead samples were diluted 50 
times with fresh TSB medium first. Each proportion of live/dead P. aeruginosa was mixed with 
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SYBR Green I/PI dye into each well of 96-well plate and the green/red fluorescence ratios were 
measured as described above, generating standard curve and equation with least-square fitting 
analysis. We used this equation to calculate the percentage of live cells of P. aeruginosa. 
Fluorescence microscopy imaging visualizing live and dead cells was performed using a 
Keyence BZ-X710 Fluorescence Microscope and was processed by BZ-X Analyzer provided by 
Keyence (Osaka, Japan). 
 
The MIC (minimum inhibitory concentration) determination 
The standard microdilution method was used to determine the MIC of each antibiotic as 
described [29-31]. P. aeruginosa (1x109 CFU/mL) was inoculated (10 μL) into each well of 96-
well plate containing 90 μL fresh TSB medium per well. Then each antibiotic was added into the 
well and the serial dilutions of drug treatment were made from 16, 8, 4, 2, 1 and 0 μg/mL. All 
experiments were run in duplicate or triplicate. The 96-well plate was incubated in 37 ℃ 
incubator overnight. The MIC is the lowest concentration of the antibiotic that prevented visible 
growth of P. aeruginosa.  
 
P. aeruginosa biofilm preparation 
The P. aeruginosa biofilm model was prepared based on the protocol as described [32]. We 
first inoculated P. aeruginosa PAO-1 strain in a 5 mL fresh TSB culture and let it grow to 
stationary phase overnight. Then this stationary phase culture was diluted 1:100 in fresh TSB 
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medium, and 100 μL diluted culture was pipetted into each well of 96-well plate and then the 
covered plate was put into 37 ℃ incubator overnight and P. aeruginosa biofilm attached on the 
bottom of the plate after removing the supernatant medium by pipetting on the side of the well 
while leaving the biofilm formed at the bottom of the plate intact. 
 
Drug combination assay on P. aeruginosa stationary phase persister model and biofilm 
model in vitro 
 Based on the Johns Hopkins Hospital Antibiotics Guideline [7], using high doses of 
synergistic antibiotic combination (β-lactam + aminoglycoside) is considered to be able to 
improve outcomes of serious P. aeruginosa infections in immunocompromised hosts [33]. As for 
the multi-drug resistant Gram-negative bacterial strains, colistin can be added to the above 
double combination [9]. The fluoroquinolones are broad-spectrum antibiotics with particular 
activity against gram-negative organisms, especially Pseudomonas aeruginosa [34]. But the 
commonly used ciprofloxacin and levofloxacin always cause increasing antibiotic resistance [7], 
so they are not recommended as empiric monotherapy in serious P. aeruginosa infection. Thus, 
we tried to investigate the function of some new fluoroquinolone derivatives like clinafloxacin. 
We evaluated Clinafloxacin (1.5 μg/mL) in combination with Cefuroxime (Cmax: 5 μg/mL), 
Gentamicin (Cmax: 10 μg/mL) and Colistin (Cmax: 5 μg/mL) separately. Colistin was replaced 
by Clinafloxacin in the clinically used triple drug combination Cefuroxime + Gentamicin + 
Colistin. The designed drug combinations or their single or two drug controls were added 
 10 
directly to stationary phase culture and CFU count was performed after 2 day and 4 day drug 
treatment. For the biofilm model, the designed drug combinations were prepared with MOPS 
buffer (1X) (diluted from 10X MOPS from Sigma-Aldrich) to the final drug concentration and 
then transferred in to 96-well plate with P. aeruginosa biofilm attached to the bottom. Biofilm 
was washed with phosphate buffered saline (PBS) before plating for CFU count. 
 
Preparation of inoculum for infection of mice 
P. aeruginosa PAO-1 was cultured in 5 mL TSB at 37 ℃ with shaking overnight. The 
culture was centrifuged 2,700 x g for 15 minutes at 4 ℃ and the bacterial cell pellet was 
resuspended in 1 ml PBS. To create a persistent infection of the lung, the concentrated bacterial 
culture was mixed with 9 ml of liquid TSA pre-equilibrated at 50 ℃, and was mixed with heavy 
mineral oil to embed bacteria in agar beads to be used for the infection, using the procedure as 
described [35]. The challenge inoculum of P. aeruginosa was established by a pilot experiment 
to be 107 CFU/mL for C57BL/6 mice. 
 
Persistent P. aeruginosa lung infection mouse model 
C57BL/6 male mice (22-22g, 6-8 week old) from Charles River were used for infection as 
described [35]. Before challenge, mice were anesthetized with ketamine (50 mg/mL) and 
xylazine (5 mg/mL) in 0.9 % NaCl administered at a volume of 0.002 mL/g body weight by 
intraperitoneal injection. After mice were fully anaesthetized, they were placed in supine 
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position, followed by intra-tracheal instillation with 50 μl of agar beads containing bacterial 
suspension (107 CFU/mL) to infect mice. A persistent lung infection that is difficult to heal is 
created due to the use of agar beads, mineral oil and stationary phase culture used for infection.  
 
Drug treatment in mouse persistent lung infection 
Based on a pilot experiment, at 3 day post-infection, mice would have the highest 108 
CFU/mL count and establish a stable persistent lung infection model as shown in the previous 
study [35]. To evaluate different drugs and drug combinations, the following groups of mice 
were used with each group having 5 mice per group: (1) drug free control (PBS); (2) cefuroxime 
(40 mg/kg) + gentamicin (30 mg/kg) treatment; (3) cefuroxime + clinafloxacin (40 mg/kg) 
treatment; (4) cefuroxime + gentamicin + levofloxacin (40 mg/kg) treatment; (5) clinafloxacin 
treatment; (6) cefuroxime + gentamicin + clinafloxacin treatment. Mice were treated daily 
intraperitoneally. After 7 day treatment, the mice were sacrificed and the whole lung of each 
mouse was excised aseptically and homogenized in 1 mL PBS, and 100 μL of appropriately 
serial diluted lung homogenates were plated on TSA plate, followed by incubation at 37 ℃ 
overnight for CFU count.  
Statistical Analysis 
Statistical analysis was performed using two-tailed Student’s t-test and two-way ANOVAs 
where appropriate. Mean differences were considered statistically significant if p was <0.05. All 
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experiments were performed in triplicates. Analyses were performed using GraphPad Prism and 




















Use of SYBR Green I/PI assay to assess the viability of P. aeruginosa  
The SYBR Green I/PI assay is a rapid and convenient method to assess bacterial viability 
under drug exposure at different time points [23]. Thus, we first optimized the SYBR Green I/PI 
assay for use in determining P. aeruginosa viability. To generate a standard curve, we combined 
live and isopropyl-killed P. aeruginosa samples in ratios of 0:10, 1:4, 5:5, 4:1, 10:0 and after 
staining with SYBR Green I/PI, the green (live) and red (dead) fluorescence intensities of the 
samples were measured using a microplate reader (BioTek Instrument). A linear relationship (R2 
values of 0.90561) between the ratios of green /red fluorescence and the percentages of live P. 
aeruginosa bacterial cells was established (Figure 1A). Fluorescence microscopy imaging 
confirmed the varying proportions of live and/or dead bacteria (Figure 1B).  
 
Ranking of major classes of antibiotics for activity against stationary phase P. aeruginosa  
To determine the relative activity of different classes of antibiotics against stationary phase 
P. aeruginosa, we performed drug exposure assays (all at 25 μM) with cell wall inhibitor (e.g. 
Cefuroxime), cell membrane inhibitor (Colistin), DNA synthesis inhibitor (e.g. Clinafloxacin), 
protein synthesis inhibitor (e.g. Gentamicin), RNA synthesis inhibitor (e.g. Rifampicin), Sulfa 
drug (e.g. Sulfamethoxazole), and Nitrofurantoin against P. aeruginosa stationary phase bacteria 
(Figure 2A). After 2-day exposure, Clinafloxacin showed the highest activity in killing stationary 
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phase bacteria, resulting in 0 CFU (Figure 2B). Cefuroxime and Colistin, cell wall and cell 
membrane inhibitors, respectively, and Sulfamethoxazole had high activity against stationary 
phase bacteria compared with the drug free control. In contrast, Gentamicin, Rifampicin and 
Nitrofurantoin showed poor activity against the stationary phase P. aeruginosa. 
Although the standard CFU assay can be used to evaluate the activity of antibiotics against 
stationary phase P. aeruginosa, we wanted to rank the same antibiotics by using the SYBR 
Green I/PI assay which is a more rapid method that can be used for high-throughput drug screens 
[23]. Our results generated by SYBR Green I/PI viability assay correlated with the results of the 
CFU counting assay (Figure 3A). Cefuroxime and Colistin, Sulfamethoxazole and Clinafloxacin 
had among the highest activity against the stationary phase P. aeruginosa. The other three 
classes of antibiotics as represented by Gentamicin, Rifampicin and Nitrofurantoin had poor 
activity. We then calculated the residual viable bacteria cells after 10-day drug exposure through 
the regression equation (Table 1). After 10 days of treatment, Colistin killed the highest number 
of stationary phase bacteria, and Cefuroxime, Sulfamethoxazole and Clinafloxacin also showed 
remarkable effects with low percentages of residual viable bacterial cells remaining (Figure 3B). 
Like our results from CFU counting, the other three classes of antibiotics as represented by 
Gentamicin, Rifampicin and Nitrofurantoin killed fewer stationary phase bacteria with 
considerable numbers of residual viable cells remaining after treatment.  
Fluorescence microscopy analysis also confirmed that Cefuroxime, Colistin, Clinafloxacin 
and Sulfamethoxazole had the highest activities against stationary phase bacteria (Figure 4). At 
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10 day post-treatment, the majority of the bacterial cells were dead (as depicted in red PI stain) 
and the numbers of viable live cells (depicted in green SYBR Green stain) were minimal. In 
contrast, stationary phase bacteria treated with Gentamicin, Rifampicin or Nitrofurantoin had 
more viable bacterial cells than dead cells, indicating their poor activity in killing stationary 
phase bacteria. Although these six classes of antibiotics all had activity against stationary phase 
bacteria compared to the drug free control, their relative activity against P. aeruginosa was quite 
different. From our CFU counts and our SYBR Green I/PI results, the six classes of antibiotics 
ranked from highest to lowest activity are as follows: clinafloxacin > colistin > gentamicin > 
cefuroxime > sulfamethoxazole > rifampicin > nitrofurantoin (Table 1).  
 
Cefuroxime exhibits greater activity against stationary phase P. aeruginosa than other cell 
wall inhibitors 
Cell wall inhibitors usually do not have good activity against persisters. Here, we found that 
cefuroxime at 25 μM reduced stationary phase bacteria from 109 to 106 CFU/mL (Figure 2B). To 
determine if it is the specific activity of cephalosporin cefuroxime against persisters, we tested 
other cell wall inhibitors such as amoxicillin and meropenem and found that compared to the 
dramatic persister killing activity of cefuroxime, amoxicillin and meropenem had limited activity 
against P. aeruginosa persisters as more than 107 CFU/mL bacteria remaining after 7-day drug 
exposure (Figure 5A). 
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Clinafloxacin exhibits the highest activity against stationary phase P. aeruginosa among 
different quinolone antibiotics 
Since we found clinafloxacin had excellent activity against stationary phase bacteria (Figure 
2B), we wanted to compare its activity with that of currently recommended quinolone antibiotics 
ciprofloxacin and levofloxacin in the treatment of P. aeruginosa infection [7], in terms of their 
activity against stationary phase P. aeruginosa. With the same 25 μM concentration, we found 
that only clinafloxacin could eradicate P. aeruginosa persisters only after 2 days by CFU count 
(Figure 5B). In contrast, ciprofloxacin and levofloxacin treatment still had 103 and 104 CFU/mL 
remaining, respectively. 
 
Relationship between the MIC values of antibiotics and their activity against stationary 
phase P. aeruginosa  
Antibiotics with a low MIC value may have great activity against growing bacteria but may 
not have strong activity against stationary bacteria and vice versa in previous studies with S. 
aureus and E coli [36-38]. Thus, we also tried to make a ranking among the six major classes of 
antibiotics (cell wall inhibitor, cell membrane disruptor, protein synthesis inhibitor, DNA 
synthesis inhibitor, RNA synthesis inhibitor, and anti-metabolite folate inhibitor) for their ability 
to kill growing log-phase bacteria. Based on the MIC values determined, our data showed that 
Colistin and Clinafloxacin had the lowest MIC values for P. aeruginosa PAO-1 strain (Table 2), 
which demonstrated that these two antibiotics can effectively kill both log phase and stationary 
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phase bacteria. We also observed that Gentamicin was highly active against log phase bacteria 
but had low activity against stationary phase bacteria. Conversely, Cefuroxime and 
Sulfamethoxazole were less effective against growing PAO-1 bacteria, both with MICs above 16 
μg/mL, but were effective in killing stationary phase bacteria (Tables 1 & 2). Rifampicin and 
Nitrofurantoin had low activity against both growing and stationary phase P. aeruginosa.  
 
Development of drug combinations to eradicate P. aeruginosa biofilms in vitro 
The bacterial cells within a biofilm structure are heterogeneous and contain persister cells 
that are tolerant to antibiotics [39]. Our previous work with B. burgdorferi biofilm-like structures 
indicated that a drug combination approach utilizing drugs active against growing bacteria and 
non-growing persister bacteria respectively is required to more effectively eradicate biofilm 
bacteria [40]. Using the drugs that we have ranked with high activity against P. aeruginosa 
stationary phase persister cells, we tested the activity of various two-drug combinations (at 
clinically relevant Cmax concentrations) in killing stationary phase cells and biofilms. Our data 
demonstrate that only Clinafloxacin as a single drug could kill stationary phase cells completely 
(109 CFU/mL) after 4-day treatment, while single drugs such as colistin, cefuroxime, and 
gentamicin could kill only about 2-logs of stationary phase cells (Figure 6A). By adding 
Cefuroxime (a drug that has great activity killing growing bacteria) to the combination with anti-
persister drug clinafloxacin, the time to kill all stationary phase cells and biofilms was shortened 
from 4 days to 2 days. Compared to the clinical treatment cefuroxime + gentamicin + colistin, 
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our designed drug combination cefuroxime + gentamicin + clinafloxacin could kill all biofilm 
bacteria (109 CFU/mL) after 4-day drug treatment, while single drugs or two drug combinations 
without clinafloxacin could kill only about 3-logs of biofilm cells and the two drug combinations 
with clinafloxacin could kill biofilm bacteria significantly with 102 CFU/mL remaining (Figure 
6B). In contrast, two-drug combinations such as colistin + gentamicin or cefuroxime + 
gentamicin, a combination currently used clinically, and even a three-drug combination 
cefuroxime + gentamicin + colistin only killed about 103-104 stationary phase and biofilm cells 
in 4 days, suggesting that a combination without an anti-persister drug (e.g. clinafloxacin) is not 
as effective. While the two-drug combination of colistin + gentamicin could also kill stationary 
phase cells by 108 CFU/mL after 4-day treatment, this combination is ineffective against biofilms 
which still remains 106 CFU/mL bacterial cells. 
 
Cefuroxime + Gentamicin + Clinafloxacin drug combination successfully eradicated 
persistent P. aeruginosa infection in cystic fibrosis model in mice 
Since we found that cefuroxime + gentamicin + clinafloxacin completely eradicated 
stationary phase culture and biofilms in vitro, we wanted to test if this triple persister drug 
regimen could also eradicate the persistent P. aeruginosa infection in vivo. To do so, we utilized 
a cystic fibrosis persistent P. aeruginosa infection model in mice as described [35]. Mice were 
infected with stationary phase P. aeruginosa PAO-1 mixed in beads through intra-tracheal 
instillation as described in Methods. After 3 day infection, bacteria reached peak at about 108 
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CFU/g of the infected lungs when different treatments were started and continued for 7 days. 
There was a modest decrease of bacterial load (103 fold) in the un-treated group after 7 days due 
to the host immune clearance of the bacterial infection [35]. After 7-day drug treatment, the 
current clinical recommended drug combination Cef + Gen only reduced the bacterial load from 
108 CFU/g to 104 CFU/g (Figure 7). Clinafloxacin (Clin) alone, or Cef + Clin, reduced the 
bacterial load to 104 or 103 CFU/g, respectively, but were unable to completely clear the bacterial 
load in the lungs. In contrast, only Cef + Gen + Clin combination cleared all bacteria in the 
infected lungs. When we replaced Clin with levofloxacin (Lev) in the drug combination, we 
found that Cef + Gen + Lev combination was unable to clear the bacterial load and still had close 
to 104 CFU/g remaining, indicating that the complete sterilization of the bacterial load is a 
property of Clinafloxacin in the context of combination with Cef and Gen. Thus, drug 
combination with clinafloxacin in this persistent lung infection model validated our in vitro drug 





















Table 1. Ranking of antibiotic activity from highest to lowest based on the amount of residual 
viable cells of P. aeruginosa (Drug concentration: 25 μM) 
*The residual viable P. aeruginosa cells were calculated from a regression standard curve and 









Drug Name Residual viable cells (%)














Table 2. Comparison of major classes of antibiotics and their respective activity against growing 
















Cefuroxime 16 4.1-7.0 + 
Cell membrane 
disruptors 
Colistin 4 2.4 +++ 
Protein synthesis 
inhibitor 
Gentamicin 1 5-12 + 
DNA synthesis 
inhibitor 
Clinafloxacin 1 1.5-2.1 +++ 
RNA synthesis 
inhibitor 
Rifampicin 16 8.2-11.7 - 
Sulfa drug Sulfamethoxazole 16 46.3 ++ 






Figure 1. SYBR Green I/PI staining can assess the viability of P. aeruginosa (A) A standard 
curve revealed linear relationship between the Green/Red fluorescence ratios from SYBR Green 
I/PI viability assay and the percentage of live P. aeruginosa PAO-1 cells. The dead organisms 
were prepared with 70 % isopropyl alcohol and different proportions of live and dead cells were 
mixed and stained with SYBR Green I/PI and the green/red fluorescence ratios were measured 
by a microplate reader. (B) Representative microscope images of 0%, 50% and 100% of live P. 
aeruginosa cells using SYBR Green I/PI stain (200 X magnification). Green cells represent live 








Figure 2. Ranking of the six classes of antibiotics by their activities against stationary phase 
P. aeruginosa determined by CFU assay (A) Structures of the selected six different classes of 
antibiotics tested against stationary phase P. aeruginosa PAO-1 strain. (B) After 10-day drug 
exposure (25 μM), the activity of each antibiotic against stationary phase P. aeruginosa was 































Figure 3. Ranking of the six classes of antibiotics by their activity against stationary phase 
P. aeruginosa determined by SYBR Green I/PI viability assay. (A) After staining the 
bacterial culture with SYBR Green I/PI in the 96-well plate, the green/red fluorescence ratios 
were measured. SYBR Green I/PI viability assay revealed drug activity results in concordance 
with the CFU assay. Cefuroxime and Colistin, Sulfamethoxazole and Clinafloxacin had good 
activity against stationary phase P. aeruginosa. (B) The percentage of residual viable cells after 




































Figure 4. Fluorescence microscopy confirmation of stationary phase P. aeruginosa PAO-1 
treated with six different classes of antibiotics (25 μM) followed by staining by SYBR Green 
I/PI assay (200X magnification). (a) Drug-free control, (b) Cefuroxime, (c) Colistin, (d) 
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Figure 5. Comparison of relative activity of different cell wall inhibitors and different 
quinolone antibiotics against stationary phase P. aeruginosa by CFU assay. Stationary phase 
cultures of P. aeruginosa were exposed to different cell wall inhibitors (25 μM) (A) or different 
quinolone antibiotics (25 μM) for 0, 2, 4, 7 days when the CFU count was performed after 
washing and serial dilutions as described in Methods. Cefuroxime (Cef); Amoxicillin (Amo); 











Figure 6. Comparison of the relative activity of different antibiotic combinations against stationary 
phase P. aeruginosa and biofilm bacteria by CFU assay. The effects of Clinafloxacin in drug 
combinations against stationary phase P. aeruginosa (A) and against P. aeruginosa biofilm model (B) 
were evaluated in drug exposure assays as described in Methods. CFU assay was performed on Day 0, 2, 
4 after washing and serial dilutions. Cefuroxime (Cef): 5 μg/mL; Gentamicin (Gen): 10 μg/mL; Colistin 








Figure 7. Cefuroxime + Gentamicin + Clinafloxacin drug combination successfully 
eradicated P. aeruginosa persistent infection in mouse cystic fibrosis model. Persistent P. 
aeruginosa lung infection in mice was established as described in Methods. The treatment was 
started 3 days after infection and continued for 7 days when the CFUs from the lungs were 
determined. The treatment groups are as follows: before treatment group; drug-free control; 
Cef+Gen; Cef+Clin; Cef+Gen+Lev; Clin; Cef+Gen+Clin. Drug dosages used were Cef 40 










DRUG COMBINATIONS TARGETING GROWING AND PERSISTER 
CELLS ERADICATE CHRONIC CARBAPENEMASE-PRODUCINT 




















Carbapenemase-Producing Klebsiella pneumoniae 
Klebsiella pneumoniae is a Gram-negative bacterium that can cause both nosocomial and 
community-acquired pneumonia [41]. K. pneumoniae is now the second most common cause of 
Gram-negative bacteremia and a major pathogen in hospital-acquired infections, particularly in 
immunocompromised patients [42]. K. pneumoniae is an opportunistic pathogen that can cause 
severe hospital-acquired infections such as septicemia, pneumonia, urinary tract infection and 
soft tissue infection in debilitated individuals [43]. Since 1980s, the management of infections 
due to K. pneumoniae has been complicated by the emergence of antimicrobial resistance [44]. 
From early this decade, Enterobacteriaceae that produce Klebsiella pneumoniae 
carbapenemases (KPC) were reported in the USA and subsequently worldwide [45]. These KPC-
producing bacteria are predominantly involved in nosocomial and systemic infections.  
 
Antibiotic Resistant KPC and KPC Biofilms 
 Based on the Johns Hopkins Antibiotic Guide [7], KPC confers broad antibiotic resistance 
and is associated with high mortality rate [46], so their susceptibility is limited to gentamicin, 
colistin and tigecycline. However, monotherapy such as single tigecycline treatment is associated 
with higher treatment failure rates compared to combination therapy when managing infections 
due to KPC-producing bacteria, particularly when treating respiratory infections [47]. Thus, 
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combination therapy is recommended. But, which antimicrobial combination is superior has yet 
to be established. 
There are many different mechanisms of resistance to carbapenems in K. pneumoniae [48]. 
The co-occurrence of permeability defects, together with the production of β-lactamases that 
possess very weak carbapenemase activity, may lead to reduced susceptibility to carbapenems, 
particular ertapenem [49]. In addition, the mechanisms involving β-lactamases (e.g., ESBLs, 
AmpC), which are not considered significant carbapenem-hydrolyzing enzymes, true 
carbapenemases are also responsible for nonsusceptibility to carbapenems without additional 
permeability defects in K. pneumoniae [50]. Infections with K. pneumoniae strains with the 
ability to form biofilms are more difficult to treat [51]. Previous researchers found that nearly 
half of 40 examined KPC strains were able to form obvious biofilms, including 13 that exhibited 
high levels of biofilm formation [52]. The antibiotic resistance of mature bacterial biofilm is 10–
1,000 times that of planktonic bacteria, and bacteria in biofilms can resist phagocytosis as well as 
host immune responses, making them very challenging to be eliminated [53]. 
 
An optimized SYBR Green I/PI Assay for Rapid Viability Assessment for KPC 
 Then conventional antibiotic susceptibility test is the Kirby–Bauer disk diffusion assay used 
to determine the susceptibility of the various strains to antibiotics. Instructions and interpretation 
of zone diameters were made using the established standards as listed in the Clinical and 
Laboratory Standards Institute [54]. In order to expedite the process of antimicrobial 
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susceptibility testing, we developed a novel approach using SYBR Green I/Propidium iodide (PI) 
staining viability assay for KPC viability assessment [55], which the lab initially developed for 
quantifying the viability and drug screens of Borrelia burgdorferi [23]. The advantages of using 
SYBR Green I/PI Assay to assess the viability of bacterial pathogens and susceptibility to 
antibiotics have been described in Chapter 1. Here, we applied the SYBR Green I/PI viability 
assay to k. pneumoniae and ranked six major classes of antibiotics in killing growing and 
stationary non-growing forms of KPC compared with conventional CFU based viability assay. 
Using these methods, we also identified drug combinations that could more effectively eradicate 















Materials and Methods 
 
Bacterial strain, culture media and growth condition 
K. pneumoniae carbapenemase strain (Isolate 7) was obtained from ATCC (Manassas, VA, 
USA). KPC strain was cultured in tryptic soy broth (TSB) and tryptic soy agar (TSA) from 
Becton Dickinson (Franklin Lakes, NJ, USA) at 37 ℃. The culture was incubated at 37℃ with 
shaking at 200 rpm. After overnight incubation, stationary phase cultures were exposed to 
different antibiotics and incubated at indicated times before washing and plating on TSA plates 
for colony forming unit (CFU) enumeration. The plates were incubated at 37 ℃ incubator 
overnight. 
 
Preparation of antibiotics 
Stock solutions of antibiotics Cefuroxime, Colistin, Gentamicin, Clinafloxacin, Rifampicin, 
Sulfamethoxazole and Nitrofurantoin (Sigma Aldrich Co.) were prepared in the laboratory, filter-
sterilized and with appropriate solvents at 10 mg/ml. Each antibiotic (25 μM) was added into 500 
μL of stationary phase culture of KPC and was incubated at 37 ℃ without shaking for various 
times. In addition, appropriate concentrations of the antibiotics were used for MIC determination 
using the microdilution method in 96-well plates (see below). 
 
Drug exposure assay by CFU counting on plates 
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Viable bacterial cells were determined by CFU count after drug exposure at days 2, 4, 6 and 
10 as described [28]. First, bacterial suspensions (50 μL) after drug exposure were washed with 
fresh TSB medium twice and serial dilutions were prepared. 10 μL of each dilution was dropped 
onto TSA plates in triplicate followed by incubation at 37 ℃ overnight. The CFU/ml was 
calculated accordingly. 
 
SYBR Green I/PI assay for KPC 
 SYBR Green I (10,000X stock, Invitrogen) was mixed with PI (20 mM, Sigma) in distilled 
H2O. The staining dye for K. pneumoniae was made by mixing SYBR Green I to PI (3:1) in 100 
μl distilled H2O which was developed by the previous lab members [55]. The drug treated 
samples were aliquoted and diluted 1:50 with fresh TSB medium. The SYBR Green I/PI dye mix 
(10 µL) was added to each 100 µL of sample. Each sample was vortexed and incubated at room 
temperature in the dark for 20 minutes. After incubation, each sample was transferred into 96-
well plate. With excitation wavelength of 485 nm and 538 nm and 612 nm for green and red 
emission, respectively, the green and red fluorescence intensity was determined for each sample 
using a Synergy H1 microplate reader by BioTek Instruments (VT, USA). To generate the 
regression equation and regression curve of the relationship between the percentage of live 
bacteria and green/red fluorescent ratios, different proportions of live and 70% isopropyl alcohol 
killed dead cells were prepared (0:10, 1:4, 5:5, 4:1, 10:0) and both live and dead samples were 
diluted 50 times with fresh TSB medium first. Each proportion of live/dead KPC was mixed with 
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SYBR Green I/PI dye into each well of 96-well plate and the green/red fluorescence ratios were 
measured as described above, generating standard curve and equation with least-square fitting 
analysis. We used this equation to calculate the percentage of live cells of KPC. Fluorescence 
microscopy imaging visualizing live and dead cells was performed using a Keyence BZ-X710 
Fluorescence Microscope and was processed by BZ-X Analyzer provided by Keyence (Osaka, 
Japan). 
 
The MIC (minimum inhibitory concentration) determination 
The standard microdilution method was used to determine the MIC of each antibiotic as 
described [29-31] and was used the same as we did on P. aeruginosa in Chapter 1. KPC (1x109) 
was inoculated (10 μL) into each well of 96-well plate containing 90 μL fresh TSB medium per 
well. Then each antibiotic was added into the well and the serial dilutions of drug treatment were 
made from 16, 8, 4, 2, 1 and 0 μg/mL. All experiments were run in duplicate or triplicate. The 
96-well plate was incubated in 37 ℃ incubator overnight. The MIC is the lowest concentration 
of the antibiotic that prevented visible growth of KPC.  
 
KPC biofilm preparation 
The KPC biofilm model was prepared based on the protocol as described [32]. We first 
inoculated KPC bacterial cells in a 5 mL fresh TSB culture and let it grow to stationary phase 
overnight. Then this stationary phase culture was diluted 1:100 in fresh TSB medium, and 100 μl 
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diluted culture was pipetted into each well of 96-well plate and then the covered plate was put 
into 37 ℃ incubator overnight and KPC biofilm attached on the bottom of the plate after 
removing the supernatant medium by pipetting on the side of the well while leaving the biofilm 
formed at the bottom of the plate intact. 
 
Drug combination assay on KPC stationary phase persister model and biofilm model in 
vitro 
 Based on the Johns Hopkins Hospital Antibiotics Guideline [7], using high doses of colistin 
(Coli) in the combination of tigecycline (Tige) is considered to be able to improve outcomes of 
serious infections in immunocompromised hosts [46]. However, there is a large concern for 
nephrotoxicity and neurotoxicity caused by colistin treatment [7]. We evaluated Clinafloxacin 
(1.5 μg/ml) (Clin) in combination with Cefuroxime (Cmax: 5 μg/ml) (Cef), Rifampin (Cmax: 10 
μg/ml) (Rif), Clarithromycin (Cmax: 2 μg/ml) (Cla) and Colistin (Cmax: 5 μg/ml) separately. 
Based on our findings on triple drug combinations against P. aeruginosa chronic infection, we 
also tested the triple drug combinations of Cef + Gen + Clin, Cef + Rif + Clin, Cef + Cla + Clin 
and Cef + Coli + Clin for their activities against KPC in biofilm model in vitro. The designed 
drug combinations or their single or two drug controls were added directly to stationary phase 
culture and CFU count was performed after 2-day and 4-day drug treatment. For the biofilm 
model, the designed drug combinations were prepared with MOPS buffer (1X) (diluted from 
10X MOPS from Sigma-Aldrich) to the final drug concentration and then transferred in to 96-
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well plate with KPC biofilm attached to the bottom. Biofilm was washed with phosphate 
buffered saline (PBS) before plating for CFU count. 
 
Statistical Analysis 
Statistical analysis was performed using two-tailed Student’s t-test and two-way ANOVAs 
where appropriate. Mean differences were considered statistically significant if p was <0.05. All 
experiments were performed in triplicates. Analyses were performed using GraphPad Prism and 



















Use of SYBR Green I/PI assay to assess the viability of KPC  
The SYBR Green I/PI assay is a rapid and convenient method to assess bacterial viability 
under drug exposure at different time points [23]. Thus, we first optimized the SYBR Green I/PI 
assay for use in determining KPC viability. To generate a standard curve, we combined live and 
isopropyl-killed KPC bacterial cells samples in ratios of 0:10, 1:4, 5:5, 4:1, 10:0 and after 
staining with SYBR Green I/PI, the green (live) and red (dead) fluorescence intensities of the 
samples were measured using a microplate reader (BioTek Instrument). A linear relationship (R2 
values of 0.84553) between the ratios of green /red fluorescence and the percentages of live KPC 
bacterial cells was established (Figure 1A). Fluorescence microscopy imaging confirmed the 
varying proportions of live and/or dead bacteria (Figure 1B).  
 
Ranking of major classes of antibiotics for activity against stationary phase KPC 
To determine the relative activity of different classes of antibiotics against stationary phase 
KPC, we performed drug exposure assays (all at 25 μM) with cell wall inhibitor (e.g. 
Cefuroxime), cell membrane inhibitor (Colistin), DNA synthesis inhibitor (e.g. Clinafloxacin), 
protein synthesis inhibitor (e.g. Gentamicin), RNA synthesis inhibitor (e.g. Rifampicin), Sulfa 
drug (e.g. Sulfamethoxazole), and Nitrofurantoin against KPC stationary phase bacteria. After 2-
day exposure, Clinafloxacin showed the highest activity in killing stationary phase bacteria, 
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resulting in 0 CFU (Figure 2). In contrast, the clinical used Colistin showed poor activity against 
the stationary phase KPC. 
Although the standard CFU assay can be used to evaluate the activity of antibiotics against 
stationary phase KPC, we wanted to rank the same antibiotics by using the SYBR Green I/PI 
assay which is a more rapid method that can be used for high-throughput drug screens [23]. Our 
results generated by SYBR Green I/PI viability assay correlated with findings from the CFU 
counting assay (Figure 3A). Clinafloxacin had the highest activity against the stationary phase 
KPC. We then calculated the residual viable bacteria cells after 4-day drug exposure through the 
regression equation (Table 1). After 4 days of treatment, Clinafloxacin killed the highest number 
of stationary phase bacteria, and Colistin and Gentamicin also showed remarkable effects with 
low percentages of residual viable bacterial cells remaining (Figure 3B).  
Fluorescence microscopy analysis also confirmed that Clinafloxacin, Gentamicin and 
Colistin had the highest activities against stationary phase bacteria (Figure 4). At 10 day post-
treatment, the majority of the bacterial cells were dead (as depicted in red PI stain) and the 
numbers of viable live cells (depicted in green SYBR Green stain) were minimal. In contrast, 
stationary phase bacteria treated with Rifampicin or Nitrofurantoin had more viable bacterial 
cells than dead cells, indicating their poor activity in killing stationary phase bacteria. Although 
these six classes of antibiotics all had activity against stationary phase bacteria compared to the 
drug free control, their relative activity against KPC was quite different. From our CFU counts 
and our SYBR Green I/PI results, the six classes of antibiotics ranked from highest to lowest 
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activity are as follows: clinafloxacin > colistin > gentamicin > cefuroxime > sulfamethoxazole > 
rifampicin > nitrofurantoin (Table 1).  
 
Clinafloxacin exhibits the highest activity against stationary phase KPC among different 
quinolone antibiotics 
Since we found clinafloxacin had excellent activity against stationary phase bacteria (Figure 
2B), we wanted to compare its activity with that of currently recommended quinolone antibiotics 
ofloxacin and levofloxacin in the treatment of gram-negative bacterial persistent infection[56]. 
With the same 25 μM concentration, we found that only clinafloxacin could eradicate KPC 
persisters only after 2 days by CFU count (Figure 5). In contrast, ofloxacin and levofloxacin 
treatment still had 106 CFU/mL remaining, respectively. And the clinically recommended 
treatment with colistin or tigecycline could only kill 101 CFU/mL stationary phase KPC. 
 
Relationship between the MIC values of antibiotics and their activity against stationary 
phase KPC 
Antibiotics with a low MIC value may have great activity against growing bacteria but may 
not have strong activity against stationary bacteria and vice versa in previous studies with S. 
aureus and E coli [36-38]. Thus, we also tried to make a ranking among the six major classes of 
antibiotics (cell wall inhibitor, cell membrane disruptor, protein synthesis inhibitor, DNA 
synthesis inhibitor, RNA synthesis inhibitor, and anti-metabolite folate inhibitor) for their ability 
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to kill growing log-phase bacteria. Based on the MIC values determined, our data showed that 
Colistin and Clinafloxacin had the lowest MIC values for KPC (Table 2), which demonstrated 
that these two antibiotics can effectively kill both log phase and stationary phase bacteria. We 
also observed that Rifampin was highly active against log phase bacteria but had low activity 
against stationary phase bacteria. Conversely, Cefuroxime and Gentamicin were less effective 
against growing KPC bacteria, both with MICs above 16 μg/mL, but were effective in killing 
stationary phase bacteria (Tables 1 & 2). Sulfamethoxazole and Nitrofurantoin had low activity 
against both growing and stationary phase KPC.  
 
Development of drug combinations to eradicate KPC biofilms in vitro 
The bacterial cells within a biofilm structure are heterogeneous and contain persister cells 
that are tolerant to antibiotics [39]. Our previous work with B. burgdorferi biofilm-like structures 
indicated that a drug combination approach utilizing drugs active against growing bacteria and 
non-growing persister bacteria respectively is required to more effectively eradicate biofilm 
bacteria [40]. Using the drugs that we have ranked with high activity against KPC stationary 
phase persister cells, we tested the activity of various two-drug combinations (at clinically 
relevant Cmax concentrations) in killing biofilms. Compared to the clinical treatment colistin + 
tigecycline , our designed drug combination cefuroxime + rifampin + clinafloxacin could kill all 
biofilm (109 CFU/mL) after 5-day drug treatment, while single drugs or two drug combinations 
without clinafloxacin could kill only about 3-logs of biofilm cells and the two drug combinations 
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with clinafloxacin could kill biofilm bacteria significantly to 104 CFU/mL remaining (Figure 6), 












































Table 1. Ranking of antibiotic activity from highest to lowest based on the amount of residual viable cells 
of KPC (Drug concentration: 25 μM) 
*The residual viable KPC cells were calculated from a regression standard curve and equation from the 
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Table 2. Comparison of major classes of antibiotics and their respective activity against growing and 


















Cell wall inhibitor Cefuroxime >16 50-100 + 
Cell membrane 
disruptors 
Colistin 4 2.4 ++ 
Protein synthesis 
inhibitor 
Gentamicin >16 5-12 ++ 
DNA synthesis 
inhibitor 
Clinafloxacin 1 2.1 +++ 
DNA synthesis 
inhibitor 
Rifampicin 6 8.2-11.7 - 
Sulfa drug Sulfamethoxazole 16 46.3 + 








Figure 1. SYBR Green I/PI staining can assess the viability of KPC. (A) A standard curve 
revealed linear relationship between the Green/Red fluorescence ratios from SYBR Green/PI 
viability assay and the percentage of live KPC cells. The dead organisms were prepared with 
70 % isopropyl alcohol and different proportions of live and dead cells were mixed and stained 
with SYBR Green I/PI and the green/red fluorescence ratios were measured by a microplate 
reader. (B) Representative microscope images of 0%, 50% and 100% of live KPC cells using 
SYBR Green I/PI stain (200 X magnification). Green cells represent live cells and Red cells 
































Figure 2. Ranking of the six classes of antibiotics by their activities against stationary phase 
KPC determined by CFU assay (A) Structures of the selected six different classes of antibiotics 
tested against stationary phase KPC. (B) After 10-day drug exposure (25 μM), the activity of 








































Figure 3. Ranking of the six classes of antibiotics by their activity against stationary phase 
KPC determined by SYBR Green I/PI viability assay. (A) After staining the bacterial culture 

































































SYBR Green/PI viability assay revealed drug activity results in concordance with the CFU assay. 
Cefuroxime and Colistin, Sulfamethoxazole and Clinafloxacin had good activity against 
stationary phase KPC. (B) The percentage of residual viable cells after 10-day antibiotic 





























Figure 4. Fluorescence microscopy confirmation of stationary phase KPC treated with six 
different classes of antibiotics (25 μM) followed by staining by SYBR Green I/PI assay (200X 
magnification). (a) Drug-free control, (b) Cefuroxime, (c) Colistin, (d) Gentamicin, (e) 











(a) Drug free control









Figure 5. Comparison of relative activity of different quinolone antibiotics against 
stationary phase KPC by CFU assay. Stationary phase cultures of KPC were exposed to 
different cell wall inhibitors (25 μM) (A) or different quinolone antibiotics (25 μM) for 0, 2, 4, 7 
days when the CFU count was performed after washing and serial dilutions as described in 
Methods. Cip (Ciprofloxacin); Lev (Levofloxacin); Clin (Clinafloxacin); Oflo (Ofloxacin); Gati 











Figure 6. Comparison of the relative activity of different antibiotic combinations against 
KPC biofilm bacteria by CFU assay. The effects of Clinafloxacin in drug combinations against 
stationary phase KPC biofilm model were evaluated in drug exposure assays as described in 
Methods. CFU assay was performed on Day 0, 2, 5 after washing and serial dilutions. 
Cefuroxime (Cef): 5 μg/mL; Rifampin (Rif): 6 μg/mL; Colistin (Coli): 5 μg/mL; Clinafloxacin 












Clinically, it has been challenging to cure persistent infections like P. aeruginosa lung 
infections in cystic fibrosis patients and gastrointestinal colonization by KPC. The difficulty to 
cure the persistent infections is thought to be mainly due to persister bacteria that are not 
effectively killed by the current antibiotics used to treat such infections [14]. To address this 
hypothesis, here, we first ranked the six major classes of antibiotics for their activity against P. 
aeruginosa persisters in vitro and found a ranking order based on both CFU count and our SYBR 
Green I/PI results: clinafloxacin > colistin > gentamicin > cefuroxime > sulfamethoxazole > 
rifampicin > nitrofurantoin. Among different cell wall inhibitors, cefuroxime showed greater 
activity to kill P. aeruginosa persisters than amoxicillin and meropenem. Among different 
quinolone antibiotics, clinafloxacin killed all persister bacteria after 2-day drug exposure but 
other quinolones were not able to eradicate all persisters even after 7-day drug exposure, 
suggesting that clinafloxacin could be a potential persister drug candidate for inclusion in drug 
combinations to kill persisters and biofilm bacteria. Based on the Yin-Yang model [14] utilizing 
drugs with activity against growing bacteria (MICs) and anti-persister activity results, we 
designed a series of drug combinations to evaluate their ability to eradicate stationary phase or 
biofilm bacteria in vitro. Although the double drug combination of cefuroxime + clinafloxacin 
and gentamicin + clinafloxacin could eradicate persisters on day 4 treatment which has the same 
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activity as the triple therapy cefuroxime + gentamicin + clinafloxacin (Cmax as concentration of 
each drug) and effectively killed stationary phase bacteria, only the triple drug combination 
cefuroxime + gentamicin + clinafloxacin could kill all persisters after 2-day drug exposure in the 
P. aeruginosa biofilm model. To further confirm the efficacy of the triple drug combination 
cefuroxime + gentamicin + clinafloxacin in vivo, we successfully established the P. aeruginosa 
lung persistent infection mouse model using stationary phase bacteria mixed with agar beads for 
intra-tracheal instillation infection. Using this persistent lung infection model, we were able to 
validate that clinafloxacin in combination with cefuroxime and gentamicin cleared all bacterial 
infection in the mouse lungs, whereas other single drugs or two drug combinations failed to 
eradicate the P. aeruginosa persistent lung infection. We then confirmed our antibiotics ranking 
methods on KPC persistent infection in vitro. we ranked the six major classes of antibiotics for 
their activity against KPC persisters in vitro and found a ranking order based on both CFU count 
and our SYBR Green/PI results: clinafloxacin > colistin > gentamicin > cefuroxime > 
rifampicin > sulfamethoxazole > nitrofurantoin. Among different quinolone antibiotics, 
clinafloxacin killed all persister bacteria after 2-day drug exposure but other quinolones were not 
able to eradicate all persisters even after 7-day drug exposure, suggesting that clinafloxacin could 
be a potential persister drug candidate for inclusion in drug combinations to kill persisters and 
biofilm bacteria which correspond to our findings in antibiotics screenings for P. aeruginosa. 
After we tested different drug combinations for their activities against KPC biofilm model, we 
found compared to the clinically used colistin + tigecycline, only triple drug cefuroxime + 
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rifampin + clinafloxacin can eradicate the KPC biofilm model in 5-day treatment in vitro. And 
we found that when adding clinafloxacin to the colistin + tigecycline treatment, there would be a 
great decrease of bacterial cells due to the dramatic anti-persister effect from clinafloxacin. 
Based on the Johns Hopkins Hospital Antibiotics Guideline [7], drugs that are included in 
routine treatment of P. aeruginosa infections range from β-lactam, aminoglycosides, 
fluoroquinolones to polymyxins. The majority of cystic fibrosis patients suffer from chronic 
infections of the airway with P. aeruginosa and the empiric treatment for P. aeruginosa currently 
uses two active agents from two different classes of antibiotics [33]. The two drug combination 
using high doses of synergistic antibiotic combinations (β-lactam + aminoglycoside) has been 
considered to improve outcomes of serious infections in immunocompromised hosts [8]. For 
multidrug resistant strains, colistin can be added to the above treatment [9]. However, in our 
study, we found that the current recommended treatment β-lactam + aminoglycoside (Cef + 
Gen) did not completely kill P. aeruginosa stationary phase and biofilm bacteria in vitro and 
failed to sterilize the lungs in the persistent lung infection in mice. In contrast, our persister drug 
Clinafloxacin in combination with Cef + Gen completely eradicated biofilm bacteria in vitro, and 
more importantly, the persistent lung infection in mice.   
Our effective drug combination findings successfully apply the ‘Yin-Yang’ model to kill 
both replicating log phase bacteria (Yang) and also non-replicating persister bacteria(Yin) [14]. 
In the Tuberculosis (TB) therapy, isoniazid (INH) is only active for growing mycobacteria, 
rifampin (RIF) is used to kill both growing and non-growing bacteria, and pyrazinamide (PZA) 
 55 
is added to kill exclusively non-growing persister bacteria in the treatment of TB [15]. The 
importance of PZA in killing persister TB bacteria and shortening the TB therapy without relapse 
is mainly recognized in the TB field and not appreciated in other persistent infections. We 
proposed to apply the PZA persister drug principle for the treatment of other infections [57]. This 
PZA principle has been shown to be valid in subsequent studies with different bacteria such as B. 
burgdorferi [40, 58], S. aureus (Yee R et al. to be published), E. coli [59] both in vitro and in 
vivo. In this study, our findings with Clin + Cef +Gen combination both in vitro and in vivo 
further validate this PZA principle and the Yin-Yang model for developing more effective 
treatment of persistent infections, where Clin is an excellent drug targeting dormant persister 
bacteria (Yin) when used together with Cef and Gen which target growing bacterial populations 
for effective eradication of P. aeruginosa persistent lung infection. In our separate study with S. 
aureus pesistent skin infection model, we were also able to show that persister drug 
combinations utilizing the Yin-Yang model could achieve eradication of biofilm persistent 
infections (Yee, et al., to be published). Thus, we believe the PZA principle and Yin-Yang model 
can be applied for more effective treatment of other persistent infections in general.  
There remain several areas for further investigation. First, the structural basis for the anti-
persister activity in clinafloxacin fluoroquinolone drug is not clear but may be related to the 
unique chloride group in the quinolone ring. Further synthetic chemistry studies are needed to 
determine if the unique anti-persister activity is due to the chloride group and to further optimize 
the activity of clinafloxacin for anti-persister activity and to reduce its potential toxicity. Second, 
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the mechanism of the unique anti-persister activity in clinfloxacin is not known but could be due 
to its activity on the bacterial cell membrane, as it is known that several persister drugs such as 
pyrazinamide [60], daptomycin [58], and colistin [37, 59] have activity on disrupting the 
bacterial membranes [61]. Further studies are needed to understand how Clinafloxacin kills 
persisters more effectively than other fluoroquinolones. Third, despite the impressive anti-
persister activity of clinafloxacin and its compassionate use for treatment of Burkholderia 
cenocepacia infection in a cystic fibrosis patient [62], it is not an FDA approved drug because of 
its adverse drug reactions such as photosensitivity and hypoglycemia [63]. Thus, although our 
findings are encouraging, further studies are needed to address the above issues with its unique 
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